Shares of Dynavax Technologies (NASDAQ: DVAX) were jumping 5.9% higher as of 3:09 p.m. EST on Friday. The gain came after the company announced that its hepatitis B virus (HBV) vaccine Heplisav-B received marketing authorization from the European Commission (EC).
Today's news wasn't really a surprise. The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) already gave a positive approval recommendation. Heplisav-B is also already approved in the U.S.
Image source: Getty Images.
For further details see:
Why Dynavax Stock Jumped Today